Skip to Content

Angiotensin II

Medically reviewed on Sep 10, 2018

Pronunciation

(an jee oh TEN sin too)

Index Terms

  • Angiotensin 2
  • ATII

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous [preservative free]:

Giapreza: 2.5 mg/mL (1 mL)

Brand Names: U.S.

  • Giapreza

Pharmacologic Category

  • Vasoactive Agent

Pharmacology

Naturally occurring peptide hormone of the renin-angiotensin-aldosterone system (RAAS) that causes vasoconstriction and increases aldosterone release, which raises blood pressure.

Metabolism

Metabolized by aminopeptidase A and angiotensin converting enzyme 2 to angiotensin-(2-8) [angiotensin III] and angiotensin-(1-7), respectively in plasma, erythrocytes and many major organs.

Half-Life Elimination

IV: <1 minute

Use: Labeled Indications

Septic or other distributive shock: To increase blood pressure in adults with septic or other distributive shock

Contraindications

There are no contraindications listed in the manufacturer's labeling.

Dosing: Adult

Septic or other distributive shock: Continuous IV infusion: Initial: 20 ng/kg/minute; monitor response and titrate every 5 minutes by increments of up to 15 ng/kg/minute as needed. Once the underlying shock has sufficiently improved, down-titrate every 5 to 15 minutes by increments of up to 15 ng/kg/minute based on response. Doses as low as 1.25 ng/kg/minute may be used.

Maximum initial dose: 80 ng/kg/minute during the first 3 hours of treatment.

Maximum maintenance dose: 40 ng/kg/minute.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment

There are no dosage adjustments provided in the manufacturer's labeling.

Reconstitution

Dilute vial in NS to a final concentration of 5,000 ng/mL or 10,000 ng/mL:

Not fluid restricted: Dilute 2.5 mg/mL vial in 500 mL NS to a final concentration of 5,000 ng/mL

Fluid restricted: Dilute 2.5 mg/mL vial in 250 mL NS to a final concentration of 10,000 ng/mL or dilute 5 mg per 2 mL vial in 500 mL NS to a final concentration of 10,000 ng/mL

Administration

IV: Administer by continuous IV infusion via central venous line.

Storage

Store intact vials at 2°C to 8°C (36°F to 46°F). May store diluted solution at room temperature or under refrigeration ≤24 hours; discard diluted solution after 24 hours.

Drug Interactions

Angiotensin II Receptor Blockers: May diminish the therapeutic effect of Angiotensin II. Monitor therapy

Angiotensin-Converting Enzyme Inhibitors: May enhance the therapeutic effect of Angiotensin II. Monitor therapy

Adverse Reactions

Percentages are the result of combination vasopressor therapy.

>10%:

Cardiovascular: Thrombosis (13%)

1% to 10%:

Cardiovascular: Tachycardia (9%), deep vein thrombosis (4%), peripheral ischemia (4%)

Central nervous system: Delirium (6%)

Endocrine & metabolic: Acidosis (6%), hyperglycemia (4%)

Hematologic & oncologic: Thrombocytopenia (10%)

Infection: Fungal Infection (6%)

Warnings/Precautions

Concerns related to adverse effects:

• Thrombosis: Arterial and venous thrombotic and thromboembolic events have been reported; use concurrent venous thromboembolism (VTE) prophylaxis.

Monitoring Parameters

Blood pressure response.

Pregnancy Considerations

Animal reproduction studies have not been conducted. When treatment for septic or other disruptive shock is needed, delaying treatment due to pregnancy increases the risk of maternal and fetal morbidity and mortality.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Have patient report immediately to prescriber signs of acidosis (confusion, fast breathing, tachycardia, abnormal heartbeat, severe abdominal pain, nausea, vomiting, fatigue, shortness of breath, or loss of strength and energy), bruising, bleeding, tachycardia, mood changes, or signs of blood clots (numbness or weakness on one side of the body; pain, redness, tenderness, warmth, or swelling in the arms or legs; change in color of an arm or leg; angina; shortness of breath; tachycardia; or coughing up blood) (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide